Original from: 360dx

Kidney dialysis firm Fresenius Medical Care said Monday that it is selling select laboratory assets to Quest Diagnostics.

Quest is acquiring select assets of Fresenius' Spectra Laboratories business, which provides renal testing services in the US. The firms said that they also struck a separate deal for Quest to provide comprehensive lab services for end-stage kidney disease and specialized water testing for Fresenius' clinics and partner clinics in the US.

Financial and other terms of the deals were not disclosed. The acquisition is expected to be completed during the second half of 2025, although the transition period for the affected services is expected to extend into early 2026.

The firms said that the acquisition gives Quest new capabilities for testing the quality of water that is used in dialysis. Fresenius expects to gain operational efficiencies and access to Quest's chronic kidney disease and transplantation services as well as Quest's US laboratory network.

Fresenius noted that it has been divesting noncore and dilutive assets as part of a three-year transformation plan that is meant to refocus the company on the businesses and markets that provide the best strategic fit, greatest scale, and sustainable profitable growth.

"This agreement is a step forward to allow us to remain focused on our core business of providing world-class dialysis care to every patient, every day," Fresenius CEO Helen Giza said in a statement.

Quest Chairman and CEO Jim Davis added that the acquisition will help Quest to expand its chronic kidney disease testing portfolio and offer lab services closer to Fresenius' dialysis clinics and patients.

Source: Quest Diagnostics to Acquire Select Lab Assets of Fresenius Medical Care